|
January 2009 (Volume 16, Issue 1)
|
   |
Article: 582
Japan’s Global Clinical Trials Initiations Skyrocket
New global clinical trial initiations increased dramatically from 2006 to 2007 in Japan. No other country in Asia experienced anywhere near such an increase in new global clinical trial initiations.
Article: 583
2008: Strong Start, Tough Finish
2008 began with high expectations for growth in the clinical trial space, but difficult economic conditions led many companies to slow non-organic growth and cut costs. In spite of the challenges brought on by the economic and regulatory climate—or perhaps because of them—some emerging markets within the industry thrived.
Article: 584
ICH E9 a Decade Later—What’s Working, What’s Not
Experts are divided as to whether the original guideline International Conference on Harmonisation (ICH) E9, adopted in February 1998, needs further revision.
Article: 585
Eye On:Adverse Effects of Chemotherapy
Although many currently available chemotherapeutic agents are effective in prolonging survival in cancer patients, they often do so at the risk of poor tolerability and toxicity. Acute complications may include chemotherapy-related nausea or vomiting (CINV), diarrhea and mucositis, whereas chronic complications may include neutropenia or anemia due to bone marrow suppression, or nerve damage manifest as hearing loss or neuropathy.
Price: $59.00
|